// App-Quantinova.ai

: ABO Blood Group and Risk of Malignancy in Intraductal Papillary Mucinous Neoplasms

Researchers

Presenter

  • P. Zelga

Principal Investigators

  • Y. Hernandez-Barco

  • M. Qadan

  • C. Ferrone

  • A. Kambadakone

  • M. Achalandaso Boira

  • A. Jah

  • A. Warshaw

  • K. Lillemoe

  • A. Balakrishnan

  • C. Fernandez-del Castillo

Medical Centers

  • Massachusetts General Hospital, Harvard Medical School, Gastroenterology, Boston, MA, United States

  • Addenbrookes Hospital, NIHR Comprehensive Biomedical Research and Academic Health Sciences Centre, Cambridge University Hospitals NHS Foundation Trust, Department of Surgery, Cambridge, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mucinous neoplasms

  • Intraductal papillary mucinous neoplasm

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved